Sign In
Buy GLP
$48.63
+0.410 (+0.85%)
At Close: Jul 28, 2026
Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
02:06pm, Wednesday, 18'th Mar 2026
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.
Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum?
12:06pm, Wednesday, 18'th Mar 2026
LLY stock falls 6% after an HSBC downgrade flagged persisting U.S. pricing pressure, rising market competition and compounded tirzepatide risks, despite strong GLP-1 demand.
16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq:
Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound's cash sales
02:28pm, Tuesday, 17'th Mar 2026
If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.
Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk
09:33am, Tuesday, 17'th Mar 2026
Citi has kept its 'neutral' rating on Novo Nordisk (NYSE:NVO) after a rival company released clinical data showing its oral GLP-1 drug delivered weight loss broadly comparable to Novo's own obesity pi
Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target
07:45am, Tuesday, 17'th Mar 2026
Structure Therapeutics (GPCR) reported highly positive Phase 2 ACCESS II data for aleniglipron, achieving ~16% placebo-adjusted weight loss with strong statistical significance and no plateau. Alenigl
Eli Lilly Just Opened the Door to Even Greater GLP-1 Growth
11:19am, Monday, 16'th Mar 2026
Eli Lilly 's ( NYSE:LLY ) GLP-1 therapy Zepbound has become the biggest weight loss drug since its introduction, outpacing Novo Nordisk 's ( NYSE:NVO ) Wegovy in both sales momentum and patient prefer
3 Companies at the Forefront of the GLP-1 Pill Wars
07:44am, Monday, 16'th Mar 2026
Though the first GLP-1 agonists date back more than 20 years, it's only in the last couple of years that they began to dominate the pharmaceutical space for their massive potential as weight loss dru
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral G
Eli Lilly's Employer Push Could Unlock New GLP-1 Demand
08:19am, Sunday, 15'th Mar 2026
The world's most valuable pharmaceutical stock, Eli Lilly and Company NYSE: LLY, has continued to assert its dominance in the weight-loss and diabetes drug market in 2026.
Will Policy Shifts Accelerate Demand for Eli Lilly's GLP-1 Drugs?
01:51pm, Thursday, 12'th Mar 2026
LLY is likely to see stronger demand for its GLP-1 drugs as Medicare expands coverage and the company prepares to launch an oral obesity treatment.
Can Novo Nordisk's Hims & Hers Deal Revive Its GLP-1 Momentum?
10:25am, Wednesday, 11'th Mar 2026
NVO partners with HIMS to expand access to Ozempic and Wegovy via telehealth, aiming to shift patients from compounded GLP-1s to FDA-approved drugs.
Revisiting The Preferred Stock Of Global Partners
08:30am, Wednesday, 11'th Mar 2026
Global Partners (GLP.PR.B) preferred stock offers a 9.3% yield with a wide margin of safety despite recent geopolitical turmoil. GLP's resilient business model, demonstrated during past oil price shoc
Hims & Hers Health: The GLP-1 Chaos Is Fading, The Thesis Is Still On Track
04:43pm, Tuesday, 10'th Mar 2026
Hims & Hers Health, Inc. surges after securing a partnership with Novo Nordisk, resolving legal and regulatory overhangs tied to compounded GLP-1s. HIMS's long-term platform thesis centers on becoming
GLP-1 weight-loss drug race heats up as new rival matches Wegovy results with fewer side effects
12:48pm, Tuesday, 10'th Mar 2026
Citi stays 'neutral' on Novo Nordisk as crowded obesity market threatens to erode its competitive edge Novo Nordisk (NYSE:NVO), the Danish pharma giant behind the Ozempic and Wegovy weight-loss drugs,
